19 September 2025 - Subcutaneous Lunsumio has potential to substantially reduce treatment administration time with an approximately one minute injection, compared with 2-4 hours intravenous infusion.

Roche announced today that the EMA’s CHMP has recommended the approval of a subcutaneous formulation of Lunsumio (mosunetuzumab) for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.

Read Roche press release